reports
Galapagos NV: 1 director
A director at Galapagos NV bought 62,273 shares at 28.810USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- ING Helpdesk
- Livio Luyten
- Michiel Declercq
Galapagos Creates New Subscription Right Plan
Galapagos Creates New Subscription Right Plan Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new subscription right plan. On May 27, 2025, the Board of Directors of Galapagos approved “Subscription Right Plan 2025 (A)”, intended for personnel of the Company, within the framework of the authorized capital. Under this subscription right plan, 925,000 subscription rights were created, subject to acceptance, for senior management compensation p...
Galapagos creëert nieuw inschrijvingsrechtenplan
Galapagos creëert nieuw inschrijvingsrechtenplan Mechelen, België; 27 mei 2025, 22:30 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat haar Raad van Bestuur 925.000 inschrijvingsrechten heeft gecreëerd onder een nieuw inschrijvingsrechtenplan. De Raad van Bestuur van Galapagos heeft op 27 mei 2025 “Inschrijvingsrechtenplan 2025 (A)”, bestemd voor personeel van de Vennootschap, goedgekeurd binnen het kader van het toegestaan kapitaal. Onder dit inschrijvingsrechtenplan werden 925.000 inschrijvingsrechten gecreëerd in het kader voor beloningen...
- ING Helpdesk
Benelux Morning Notes
Ackermans & van Haaren: Solid 1Q25. Ascencio: Resilient results. Gimv: NAV a tad higher than expected, underlying companies surprisingly strong. IBA: Soft start in Technologies, 2025 and 2028 guidance reiterated. OCI: In-line 1Q25 trading update. Vopak: IPO of AVTL - value coming to the surface
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- Livio Luyten
- Wim Lewi
Gimv FY24-25 Results: Realizing Growth Strategy With €336m In Investme...
Gimv reported another record year. Net profit reached €219m or €7.5ps. Portfolio result was €300m, up 19.3% YoY. Investments surged to €336.1m, including €267m in eight new companies and two roll-over's. Divestments totalled €560m from exits in Mega, United Dutch Breweries, Köberl, rehaneo, and Medi-markt. The book value of these stakes was €200m, implying a money multiple of 2.4x and IRR of 14.0%. NAVps stood at €53.3, slightly down from €53.4 YoY due to the capital increase, but up 14.6% on a ...
- Jacob Mekhael
EHA abstracts Autolus, Galapagos, MaaT
The abstracts for presentations at EHA (12-15 June) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (long-term findings and predictors of sustained remission for Aucatzyl in r/r adult ALL, as well as age stratified outcomes), Galapagos (more data and follow up from its decentralised CAR-T program) and MaaT (additional data from ...
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring ...
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congre...
Galapagos kondigt mondelinge presentaties aan tijdens EHA en ICML 2025...
Galapagos kondigt mondelinge presentaties aan tijdens EHA en ICML 2025 met veelbelovende nieuwe resultaten uit de ATALANTA-1 studie met CAR-T kandidaat GLPG5101 Mechelen, België; 14 mei 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), een wereldwijd biotechnologiebedrijf dat zich toelegt op het veranderen van de resultaten voor patiënten door middel van levensveranderende wetenschap en innovatie, kondigde vandaag aan dat nieuwe gegevens uit haar lopende ATALANTA-1 fase 1/2-studie met GLPG5101 bij patiënten met recidief/refractair non-Hodgkin lymfoom (R/R NHL) geaccepteerd zijn voor ...
- Jacob Mekhael
Galapagos 1-1 mgmt. call feedback on re-evaluation of company split
We had a 1-1 call with Galapagos' mgmt. including Henry Gosebruch, newly appointed CEO, and Jérôme Contamine, newly appointed chairman of the board following this morning's announcement regarding the re-evaluation of the proposed company split in favour of strategic alternatives for the cell therapy business. Our takeaway is this new approach leads to a similar outcome intended with the split, but through a smoother path. We summarise our key takeaways in this note.
- Jacob Mekhael
- Kristof Samoy
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Jacob Mekhael
Galapagos Re-evaluates split in favour of strategic options for cell t...
Galapagos announced that the previously announced company split has been re-evaluated, and instead the company will explore strategic options for the cell therapy business. Henry Gosebruch has been appointed as CEO of Galapagos, replacing Paul Stoffels, effective immediately, and will lead the strategic evaluation process, while also focusing on building a new pipeline through business development. While we find the timing a bit of a surprise, we do note that this outcome could increase the cash...
Galapagos Announces Strategic Update on Proposed Separation, Executive...
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing resources available for transformative business development transactions Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as CEO of Galapagos, effective immediately, succeeding Dr. Paul Stoffels who announced hi...
Galapagos kondigt een strategische update aan over de geplande splitsi...
Galapagos kondigt een strategische update aan over de geplande splitsing, de transitie van het uitvoerend leiderschap, en wijzigingen in de Raad van Bestuur Galapagos heroverweegt uitvoering van eerder aangekondigde splitsing naar aanleiding van ontwikkelingen in regelgeving en de markt Galapagos onderzoekt alle strategische alternatieven voor haar bestaande activiteiten, waaronder celtherapie, met de nadruk op het maximaliseren van de beschikbare middelen voor transformatieve business development transacties De heer Henry Gosebruch is door de Raad van Bestuur van Galapagos benoemd t...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Wim Hoste
Ontex US key to the growth but limited visibility – target price lower...
Ontex is a mix of two tales, ie a mature European business which is a private label market leader in most of its activities whilst its US activities have growth potential on the back of its challenger status and much lower private label penetration. A weak start of the year, intensified competition from A-label brands and limited visibility on the mid term upside from the US business prompt us to become a bit more cautious and lower our target price from € 12 to € 10. Given the significant upsid...
- Livio Luyten
Holdings Report - April 2025 KBCS Holdings Universe Returns 2.7% Durin...
1M Performance - Absolute: During April'25 (1M period), the KBCS Holdings Universe posted a return of +2.7% which was mainly driven by multi-asset holdings (+3.0%) while single-asset holdings posted a smaller return of +2.0%. The 3 top performers during the period were D'Ieteren (+10.6%), Ackermans & van Haaren (+7.7%) and Groupe Bruxelles Lambert (+5.4%) while the 3 worst performers were Exor (-0.8%), HAL Trust (-1.5%) and Quest for Growth (-5.5%). YTD Performance - Relative: On a YTD basis (a...
GBLB GROUPE BRUXELLES LAMBERT SA
HAL HAL TRUST
DIE D'IETEREN SA
SOF SOFINA SA
SOLV SOLVAC S.A.
GIMB GIMV NV
QFG QUEST FOR GROWTH
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
HEIO HEINEKEN HOLDING N.V.
KBCA KBC ANCORA SCA
TEXF TEXAF
BREB BREDERODE S.A.
TINC TINC COMM. VA
EXO EXOR N.V.
ROCK WHITESTONE GROUP
Ontex’s annual shareholders’ meeting: All resolutions approved by a la...
Ontex’s annual shareholders’ meeting: All resolutions approved by a large majority Regulated information Aalst, Belgium, May 5, 2025 – Ontex Group NV, a leading international developer and producer of personal care products, held its annual shareholders’ meeting today. All proposed resolutions were approved by the shareholders with a large majority of votes cast. The minutes of the annual shareholders’ meeting are available on Ontex’s website at: . Enquiries Investors Geoffroy Raskin Media Catherine Weyne About Ontex Ontex is a lea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.